Remove Medical Chemistry Remove Research Remove Small Molecule
article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

DT-9046 is an orally delivered small molecule that has reached pre-IND studies – making Domain the first company to successfully advance a small molecule candidate targeting PAR2. Stephan holds a PhD in medical chemistry from University of Strasbourg in France.

article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

With over two decades of experience in biomedical research, he is leading efforts to translate breakthrough GPCR biology into differentiated therapeutic strategies that can overcome immune resistance and offer new hope to patients with limited treatment options. This strategy is exemplified by its flagship programme: DT-7012.